Healthcare

• In the September 2026 quarter, groupRevenuewas US$245 million, against US$206 million in the September 2025 quarter and US$247 million in the June 2026 quarter.

AVITA Medical reported total revenue of US$26.1 million for the quarter ended 30 September 2026, up 53% year on year and 20% sequentially. RECELL generated US$22.4 million of US revenue, Cohealyx contributed US$2.1 million and PermeaDerm US$0.6 million. GrossMarginwas 84.0%, up 270 basis points, …

Monash IVF reported FY26 revenue of AUD 269.5 million, a decline of 0.9% from AUD 271.9 million in FY25. Underlying EBITDA was AUD 53.4 million, down 19.5%, and the underlying EBITDAMarginfell to 19.8% from 24.4%. Underlying net profit after tax declined to AUD 16.1 …

Modest studies carry a statistical risk. With only 44 evaluable participants, the plausible band for the true response rate around 77% is broad, which means the underlying figure could be meaningfully lower or higher. Analysts generally look for lasting responses, safety information and additional …

In arrangements like this, the biotech partner usually expects payments tied to set development and regulatory points, and the drug's progress generally depends on the partner. When a partner halts a program, expected milestone money may never arrive, shrinking theRevenueand cash the company was …

Nurix was reportedly 38% lower on November 4, 2026, based on published coverage. The trigger was Sanofi's choice to stop SAR448272, a compound partnered with the company, and the coverage states that no milestone payments are foreseen. The coverage gives no milestone values, so …

Companies selling in several currencies can report growth that moves on exchange rates alone. Measuring at constant rates strips that influence out, so a 4% reading showsDemandmore clearly. The stock's 5% advance is larger than the sales increase, hinting that the outlook change drew …